BioPharmos Group - a leading company in the field of industrial biotechnological cultivation of rare medicinal plant cells.
Group companies are certified according to international quality standards ISO 9001:2015 and ISO 22000:2005 (HACCP).
The research center of the group is a member of the Skolkovo Innovation Center.
In 2012, BioPharmos Group was awarded the “European Grand Prix for Quality” (Grand Prix Européen de la Qualité) in the nomination “Leader in the field of innovation in biotechnology”.
The history of the company began in 1973, when the cause of the thalidomide catastrophe was unraveled at the Embryology Department of the Institute of Experimental Medicine of USSR. During thalidomide catastrophe 14 000 pregnant women in Western Europe gave birth to children with inborn anomalies. As a result of the research in Embryology Department, a model of thalidomide syndrome (Patent of the Russian Federation No. 1218812) was developed, which allowed the search for tools that reduce the risk of inborn abnormalities in children.
Start of the companyBioPharmos Group was created by scientists from the Institute of Experimental Medicine of the USSR Academy of Medical Sciences and the Physical-Technical Institute of A.F. Ioffe of the USSR Academy of Sciences.
RF Patent No. 2058786 - Polyscias filicifolia extract has the property of reducing the risk of inborn pathology in children.
BioPharmos Group introduced to the market Vitagmal®, the first biotechnological product in Russia, obtained by volumetric cultivation of the biomass of a rare medicinal plant. From the sheet Polyscias filicifolia was obtained strain - BFT-01-95, which was deposited in the All-Russian collection of cell cultures for the number 58 (RF Patent No. 2337138, 2006). Today it is the only strain of Polyscias filicifolia, registered in the All-Russian collection. On the basis of this strain, together with employees of the Research Institute of Plant Physiology RAN of K.A. Timiryazeva our company developed a technology suitable for industrial production of Polyscias filicifolia biomass in bioreactors.
PCT international WO 1996002266 A1 - Antiteratogenic agent. RF Patent No. 2066686 - Polyscias filicifolia extract has the property of reducing the toxic effect of strong alcoholic drinks on the liver and brain.
Vitagmal® is included in the List of medicines recommended for the prevention of flu, colds and SARS by the Order of the Administration of St. Petersburg No 3973/48 of 21.11.2001
Series of treatment-and-prophylactic Vitagmalin creams, effective in the prevention of allergies, vascular diseases of the legs, joint inflammation, psoriasis, mycoses has created.
Large-scale recearch of the drug Vitagmal® in the Orel were conducted under the guidance of Honored Worker of Science of the Russian Federation, Professor N. G. Kosheleva. The results of the investigation are presented in numerous reports and dissertaion by E. G. Gavrilova “Prevention of adverse environmental effects in pregnant women”. It has been proven that Polyscias filicifolia extract significantly reduces risc of adverse environmental on pregnant women and newborns. It is proved that Vitagmal® has a positive effect on the course of pregnancy in insulin-dependent diabetes.
Registration of the Trifitol®, effective for acute respiratory viral infections, chronic infectious and inflammatory processes in the oral cavity and ENT organs, with catarrhal phenomena.
RF patent №2337138 for cell culture strain Polyscias filicifolia (moore ex rounier) bailey for the production of medicines, dietary supplements and cosmetics.
Registration of Vitagmal® in Ukraine.
Vitagmal® is included in the List of Scientific Achievements of the Russian Academy of Sciences.
Vitagmal® is included in the Guidelines “Prevention and treatment of miscarriage” by the Research Institute of Obstetrics and Gynecology RAMN of. D. O. Otto.
Registration of Vitagmal® and Trifitol® in Uzbekistan.
Company Group was awarded the “European Grand Prix for Quality”, Geneva, Switzerland) in the nomination “Leader in the Application of Innovations in Biotechnology”.
Patent of the Russian Federation No. 2508295 "Synthetic peptides with non-narcotic type of analgesic action" is obtained.
BioPharmos Group brands entered the TOP-10 most popular in the target audience.
Director of Science of BioPharmos Group A. M. Kotin was awarded the prize “Expert of the Year” (“Science and Innovations” nomination) of the business publication “Expert North-West”.
International PCT WO/2013/141750 "Synthetic peptides with non-narcotic type of analgesic effect".
The BIOFARMOS Research and Development Center became a participant in the Skolkovo Innovation Center creation project.
US Patent US 9,260,482 "Synthetic peptides with a non-narcotic type of analgesic effect” is obtauned.
Experts of the Federal Institute of Industrial Property decided to include the RF patent 2508295 "Synthetic peptides with non-narcotic type of analgesic action" in the List of "100 best inventions of 2015" (p. 44, p. 60).
Canadian Patent CA 2.867.994 "Synthetic peptides with a non-narcotic type of analgesic effect” is obtained.
Patent of the Russian Federation RU 2.651.491 on mechanism of action of peptides with a nonnarcotic type of analgesic effect.
Japanese Patent JP 6.118.392 and EU Patent 2.848.629 "Synthetic peptides with a non-narcotic type of analgesic effect” are obtained.
BioPharmos Group has conducted preclinical specific activity and pharmacokinetics studies of Anodynal® (based of synthetic peptides with a non-narcotic type of analgesic effect) in accordance with GLP in Russia.
Indonesian Patent ID P000053884 "Synthetic peptides with a non-narcotic type of analgesic effect” is obtained.